ISSN: 2455 - 927X

EIJO: Journal of Humanities, Social Affair, Management and Innovative Research (EIJO– JHSAMIR)

Einstein International Journal Organization (EIJO)

Available Online at: www.eijo.in

Volume – 11, Issue – 1, January - February - 2026, Page No. : 21 – 29

Curcumin-Loaded Nanoparticles: Formulation Strategies and Therapeutic Applications

[1]Kajal Gupta, [2]Mansi Sharma

[1-2]Jaipur School of Pharmacy, Maharaj Vinayak Global University, Jaipur, Rajasthan

Abstract

Curcumin, a natural polyphenolic compound derived from turmeric, has attracted significant scientific interest due to its potent antioxidant, anti-inflammatory, antimicrobial, and anticancer properties. However, its clinical application is limited by poor aqueous solubility, rapid metabolism, low bioavailability, and instability under physiological conditions. Nanotechnology-based delivery systems have emerged as promising strategies to overcome these limitations by enhancing solubility, protecting curcumin from degradation, and improving targeted delivery. Various nanoparticle formulations, including polymeric nanoparticles, lipid-based nanoparticles, nanoemulsions, liposomes, and inorganic nanocarriers, have demonstrated improved therapeutic efficacy in preclinical and clinical studies. These systems facilitate controlled drug release, enhanced cellular uptake, and site-specific targeting, thereby improving pharmacokinetic and pharmacodynamic profiles. Despite encouraging progress, challenges related to large-scale production, long-term safety, regulatory approval, and clinical translation remain. Continued research integrating advanced formulation strategies and translational studies is essential to fully realize the therapeutic potential of curcumin-loaded nanoparticles in modern medicine.

Keywords: Curcumin Nanoparticles, Nanotechnology Drug Delivery, Bioavailability Enhancement, Controlled Release, Therapeutic Applications, Nanoformulations, Targeted Delivery, Phytochemical Nanomedicine.

1. Introduction

Curcumin is a naturally occurring polyphenolic compound obtained primarily from the rhizomes of turmeric (Curcuma longa), a plant widely used in traditional medicine, food, and cosmetics. Over the past several decades, curcumin has gained considerable scientific attention due to its broad spectrum of pharmacological activities. Numerous experimental and clinical studies have demonstrated its potent antioxidant, anti-inflammatory, antimicrobial, anticancer, neuroprotective, and cardioprotective properties. These biological activities are attributed to its ability to modulate multiple molecular targets, including inflammatory cytokines, transcription factors, enzymes, and signaling pathways involved in cellular proliferation, apoptosis, and oxidative stress. Because of these diverse mechanisms, curcumin has been investigated for potential therapeutic roles in chronic diseases such as cancer, diabetes mellitus, cardiovascular disorders, arthritis, neurodegenerative diseases, and various inflammatory conditions.

Despite its promising pharmacological profile, the clinical application of curcumin remains limited. One of the primary challenges is its extremely poor aqueous solubility, which restricts dissolution in gastrointestinal fluids following oral administration. Curcumin is highly hydrophobic, leading to low dissolution rates and inadequate absorption across the intestinal epithelium. Furthermore, it undergoes rapid metabolism in the liver and intestinal mucosa, resulting in short systemic circulation time and low plasma concentrations. Chemical instability under physiological conditions, especially at alkaline pH, further contributes to degradation and reduced therapeutic activity. These limitations collectively result in poor bioavailability, which is considered a major barrier to its clinical translation.

In addition to solubility and stability issues, curcumin also exhibits limited permeability through biological membranes. The intestinal epithelial barrier restricts the absorption of hydrophobic molecules, while enzymatic metabolism rapidly converts curcumin into inactive metabolites such as glucuronides and sulfates. Consequently, conventional oral formulations often fail to achieve therapeutic plasma levels, necessitating high doses that may not always be practical or effective. Variability in gastrointestinal conditions, food interactions, and individual metabolic differences further complicate its pharmacokinetic profile.

To overcome these challenges, researchers have explored various formulation strategies aimed at improving curcumin bioavailability. Approaches such as use of adjuvants, lipid-based formulations, cyclodextrin complexes, and micronization have shown partial success. However, these methods often provide limited enhancement or lack sustained drug delivery capability. In recent years, nanotechnology-based drug delivery systems have emerged as a highly promising solution for enhancing curcumin's therapeutic performance.

Nanoparticle-based drug delivery involves encapsulating active pharmaceutical ingredients within nanoscale carriers, typically ranging from 10 to 1000 nanometers. These carriers can be engineered from biodegradable polymers, lipids, surfactants, proteins, or inorganic materials. Encapsulation of curcumin into nanoparticles significantly enhances its aqueous solubility by increasing surface area and dispersibility. Moreover, nanoparticles protect curcumin from chemical degradation and metabolic inactivation, thereby prolonging its systemic circulation time.

Another major advantage of nanoparticle formulations is their ability to provide controlled and sustained drug release. By adjusting nanoparticle composition, size, surface charge, and structure, researchers can tailor release profiles to maintain therapeutic drug levels over extended periods. This controlled release helps minimize dose frequency and improve patient compliance. Additionally, nanoparticles can be functionalized with targeting ligands, enabling site-specific drug delivery to diseased tissues such as tumors or inflamed regions. Such targeted delivery enhances therapeutic efficacy while reducing systemic side effects.

Nanotechnology also offers opportunities to enhance cellular uptake of curcumin. Nanoparticles can cross biological barriers more efficiently than conventional formulations, facilitating improved absorption through intestinal epithelium, skin, or mucosal membranes. Some advanced nanoparticle systems are designed to respond to specific stimuli such as pH, temperature, enzymes, or redox conditions, enabling triggered drug release at the desired site of action. These smart delivery systems represent an important advancement in modern pharmaceutics.

Various nanoparticle systems have been developed for curcumin delivery, including polymeric nanoparticles, solid lipid nanoparticles, liposomes, nanoemulsions, dendrimers, micelles, and inorganic nanocarriers. Each system offers unique advantages in terms of stability, drug loading capacity, release kinetics, and targeting potential. Polymeric nanoparticles, for example, provide excellent biodegradability and sustained release properties, while lipid-based carriers improve membrane permeability and solubility of hydrophobic drugs. Liposomes and nanoemulsions have shown particular promise for enhancing oral, topical, and parenteral delivery of curcumin.

The growing interest in curcumin-loaded nanoparticles reflects the broader trend toward nanomedicine, where nanoscale technologies are applied to improve drug delivery, diagnostics, and therapeutic outcomes. Advances in materials science, pharmaceutical engineering, and biotechnology have enabled the development of increasingly sophisticated nanoparticle systems with enhanced functionality and safety. These innovations hold significant potential for translating curcumin from a traditional natural compound into a clinically effective therapeutic agent.

However, several challenges remain before widespread clinical application can be achieved. Issues such as large-scale manufacturing, long-term stability, reproducibility, safety evaluation, and regulatory approval require further attention. Additionally, comprehensive clinical trials are necessary to establish therapeutic efficacy and safety in humans. Addressing these challenges will require interdisciplinary collaboration among pharmaceutical scientists, clinicians, materials scientists, and regulatory authorities.

2. Formulation Strategies for Curcumin-Loaded Nanoparticles

The therapeutic effectiveness of curcumin is significantly limited by poor aqueous solubility, chemical instability, rapid metabolism, and low systemic bioavailability. Nanotechnology-based formulation strategies have therefore gained considerable attention for enhancing curcumin delivery. Nanoparticles provide protective encapsulation, improve dissolution behavior, enhance cellular uptake, and allow controlled or targeted drug release. Various nanoparticle systems have been explored, each offering unique advantages in terms of stability, pharmacokinetics, and therapeutic performance. The choice of formulation strategy depends on the intended route of administration, desired release profile, safety considerations, and physicochemical properties of curcumin.



2.1 Polymeric Nanoparticles

Polymeric nanoparticles are among the most extensively investigated carriers for curcumin delivery due to their biocompatibility, biodegradability, and versatile drug release characteristics. These nanoparticles are typically prepared using natural or synthetic polymers such as chitosan, poly(lactic-co-glycolic acid) (PLGA), alginate, gelatin, and polycaprolactone. Such polymers provide structural integrity to nanoparticles while protecting curcumin from degradation caused by environmental factors such as light, heat, oxygen, and enzymatic activity.

One of the primary advantages of polymeric nanoparticles is their ability to provide sustained and controlled drug release. This helps maintain therapeutic plasma concentrations of curcumin over prolonged periods, reducing dosing frequency and improving patient compliance. The polymer matrix can be engineered to control release kinetics through diffusion, erosion, or swelling mechanisms. Additionally, polymeric nanoparticles enhance curcumin stability during gastrointestinal transit, improving oral bioavailability.

Surface modification of polymeric nanoparticles further enhances their performance. Coating nanoparticles with mucoadhesive polymers like chitosan improves adhesion to mucosal surfaces, prolonging residence time in the gastrointestinal tract and enhancing absorption. Functionalization with ligands, antibodies, or peptides enables targeted delivery to specific tissues or diseased cells, increasing therapeutic efficacy while minimizing systemic side effects.

Polymeric nanoparticles also demonstrate relatively low toxicity and good biodegradability, making them suitable for repeated administration. However, challenges such as polymer selection, scale-up feasibility, and reproducibility must be carefully addressed during formulation development.

2.2 Lipid-Based Nanoparticles

Lipid-based nanoparticles represent another important strategy for curcumin delivery, particularly because curcumin is highly lipophilic. These carriers include solid lipid nanoparticles, nanostructured lipid carriers, liposomes, and nanoemulsions. Lipid nanoparticles improve solubility by incorporating curcumin into lipid matrices that enhance dissolution and absorption across biological membranes.

Solid lipid nanoparticles provide a solid lipid core that protects curcumin from degradation while allowing controlled release. Nanostructured lipid carriers, which combine solid and liquid lipids, offer improved drug loading capacity and stability compared with purely solid lipid systems. Liposomes, composed of phospholipid bilayers, can encapsulate both hydrophobic and hydrophilic compounds, making them versatile carriers for curcumin delivery.

Lipid-based nanoparticles exhibit excellent biocompatibility because their components are often physiologically acceptable lipids. These carriers enhance membrane permeability, facilitating transcellular absorption and improving systemic availability of curcumin. They are also useful for multiple routes of administration, including oral, topical, transdermal, and parenteral delivery.

Despite their advantages, lipid nanoparticles may face stability issues such as lipid oxidation, aggregation, or drug leakage during storage. Proper formulation optimization, use of stabilizers, and controlled storage conditions are essential to maintain product quality.

2.3 Nanoemulsions and Micelles

Nanoemulsions and polymeric micelles are colloidal dispersions that significantly enhance the solubility and dispersibility of hydrophobic drugs like curcumin in aqueous environments. Nanoemulsions typically consist of oil droplets dispersed in water with the help of surfactants and co-surfactants. Their small droplet size provides a large surface area, promoting rapid dissolution and improved gastrointestinal absorption.

Polymeric micelles are formed by self-assembly of amphiphilic polymers in aqueous media. These structures possess a hydrophobic core that solubilizes curcumin and a hydrophilic shell that stabilizes the micelle in biological fluids. This configuration enhances drug solubility, protects curcumin from degradation, and improves pharmacokinetic properties.

Nanoemulsions and micelles are particularly advantageous for oral and topical drug delivery. They offer high drug loading capacity, improved stability, and enhanced bioavailability. These systems also demonstrate ease of preparation compared with some other nanoparticle types, making them attractive for commercial development.

However, stability remains an important consideration. Phase separation, surfactant toxicity, and long-term storage stability must be carefully evaluated. Optimization of surfactant concentration, droplet size, and formulation conditions is essential for achieving stable and effective nanoemulsion systems.

2.4 Inorganic Nanocarriers

Inorganic nanoparticles have also been explored as curcumin delivery systems due to their unique structural and functional properties. Common examples include gold nanoparticles, silica nanoparticles, magnetic nanoparticles, and other metal-based nanocarriers. These materials offer high structural stability, tunable surface properties, and potential for targeted delivery through external stimuli such as magnetic fields or light.

Gold nanoparticles, for instance, provide excellent surface functionalization capability, enabling attachment of targeting ligands or imaging agents. Silica nanoparticles offer high surface area and pore volume, allowing efficient drug loading and controlled release. Magnetic nanoparticles can facilitate targeted drug delivery through external magnetic guidance and are also useful in diagnostic imaging applications.

While inorganic nanocarriers provide several advantages, concerns about long-term safety, biodegradability, and potential toxicity remain significant. Accumulation of non-biodegradable nanoparticles in tissues may lead to adverse biological effects, necessitating thorough toxicological evaluation. Regulatory approval for inorganic nanocarriers is therefore more challenging compared with biodegradable polymeric or lipid systems.

3. Therapeutic Applications

3.1 Anticancer Applications

Curcumin-loaded nanoparticles have attracted significant attention in cancer therapy due to their ability to enhance the bioavailability and therapeutic efficacy of curcumin. Conventional curcumin exhibits poor solubility, rapid metabolism, and limited systemic distribution, which restrict its clinical usefulness. Nanoparticle-based delivery systems overcome these limitations by improving cellular uptake, prolonging circulation time, and facilitating targeted drug delivery to tumor tissues through enhanced permeability and retention effects. These formulations have demonstrated promising anticancer activity against various malignancies, including breast, colon, prostate, and lung cancers. Mechanistically, curcumin nanoparticles modulate multiple signaling pathways involved in cell proliferation, apoptosis, angiogenesis, and metastasis, thereby improving therapeutic outcomes while reducing systemic toxicity.

3.2 Anti-Inflammatory and Antioxidant Effects

Curcumin is well known for its potent anti-inflammatory and antioxidant properties; however, its clinical application is often limited by poor pharmacokinetics. Nanoparticle formulations enhance curcumin stability, solubility, and sustained release, thereby improving its therapeutic efficiency in inflammatory disorders. These nanoformulations can inhibit proinflammatory cytokines, reduce oxidative stress, and modulate inflammatory signaling pathways more effectively than free curcumin. Such properties make curcumin nanoparticles valuable in managing chronic inflammatory conditions such as arthritis, inflammatory bowel disease, and other oxidative stress-related disorders. Sustained drug release from nanoparticles also ensures prolonged therapeutic effects with reduced dosing frequency.

3.3 Neuroprotective Applications

Curcumin nanoparticles have shown considerable potential in the treatment of neurodegenerative diseases due to their enhanced ability to cross biological barriers such as the blood–brain barrier. This improved permeability enables better delivery of curcumin to neuronal tissues, where it can exert antioxidant, anti-inflammatory, and anti-amyloidogenic effects. These properties are particularly beneficial in conditions like Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders characterized by oxidative stress, inflammation, and protein aggregation. Nanoparticle-mediated delivery also protects curcumin from rapid degradation, allowing sustained therapeutic concentrations in the central nervous system.

3.4 Antimicrobial and Wound Healing Uses

Curcumin-loaded nanoparticles exhibit significant antimicrobial activity against a broad range of microorganisms, including bacteria and fungi. Enhanced solubility and stability contribute to improved antimicrobial efficacy compared with free curcumin. In wound healing applications, these nanoparticles help reduce inflammation, minimize oxidative damage, and promote tissue regeneration. Their ability to provide controlled drug release supports continuous therapeutic action at the wound site, which accelerates healing and reduces infection risk. Additionally, nanoformulations can be incorporated into gels, films, or dressings for topical therapeutic use.

3.5 Cardiovascular and Metabolic Disorders

Nanoparticle-based curcumin delivery systems have demonstrated beneficial effects in cardiovascular and metabolic disorders by improving bioavailability and systemic distribution. These formulations help regulate lipid metabolism, reduce oxidative stress, and suppress inflammatory responses associated with cardiovascular diseases. In metabolic disorders such as diabetes and metabolic syndrome, curcumin nanoparticles have shown potential in improving insulin sensitivity, reducing hyperglycemia, and protecting against complications related to oxidative stress. Sustained release and targeted delivery further enhance therapeutic effectiveness while minimizing side effects, making these systems promising candidates for long-term management of chronic metabolic conditions.

Table 1: Challenges and Limitations of Curcumin-Loaded Nanoparticles

Challenge / Limitation	Description	Impact on Development	Possible Solutions / Future Scope
Formulation Stability	Nanoparticles may undergo aggregation, drug leakage, or degradation during storage.	Reduces shelf life and therapeutic effectiveness.	Improved stabilizers, optimized storage conditions, and advanced encapsulation techniques.
Large-Scale Manufacturing Issues	Difficulty in maintaining uniform particle size, drug loading, and reproducibility during scale-up.	Limits commercial production and consistency.	Standardized manufacturing protocols and scalable nanotechnology processes.

Regulatory Approval Barriers	Strict regulatory requirements for safety, efficacy, and quality control of nanomedicines.	Delays product approval and market entry.	Clear regulatory guidelines and extensive safety documentation.
Long-Term Safety Concerns	Potential toxicity, bioaccumulation, or unknown long-term effects of some nanocarriers.	Raises concerns about clinical acceptance.	Comprehensive toxicological studies and long-term clinical evaluation.
Clinical Translation Challenges	Promising laboratory results do not always translate into clinical success.	Slows therapeutic adoption.	Well-designed clinical trials and interdisciplinary research collaboration.

4. Future Perspectives

Future research on curcumin-loaded nanoparticles is expected to emphasize the development of biodegradable, targeted, and stimuli-responsive delivery systems capable of improving therapeutic precision and minimizing systemic side effects. Biodegradable nanocarriers derived from natural or synthetic polymers are gaining attention due to their enhanced safety profile, reduced toxicity, and improved patient acceptability. Stimuli-responsive nanoparticles, which release drugs in response to specific physiological triggers such as pH, temperature, enzymes, or oxidative stress, offer promising opportunities for site-specific drug delivery, particularly in cancer, inflammatory disorders, and chronic diseases.

Another significant direction involves the integration of advanced analytical techniques and computational tools in formulation design. Artificial intelligence, machine learning, and predictive modeling can help optimize nanoparticle characteristics, predict drug release behavior, and enhance formulation efficiency while reducing experimental time and cost. These technologies also facilitate better understanding of complex interactions between nanoparticles and biological systems, thereby improving therapeutic performance and reproducibility.

Personalized medicine is also expected to play a major role in future nanoparticle-based drug delivery. Tailoring curcumin formulations according to individual patient physiology, genetic factors, disease conditions, and metabolic responses may improve treatment efficacy and reduce adverse effects. Such approaches align with the broader shift toward precision healthcare, where therapies are designed specifically for individual patient needs.

In addition, regulatory harmonization and standardized evaluation methods are essential for the successful translation of curcumin nanomedicines from laboratory research to clinical practice. Clear regulatory guidelines regarding safety assessment, quality control, and characterization of nanomaterials will facilitate faster approval processes and greater industrial confidence. Furthermore, scalable and cost-effective manufacturing technologies must be developed to ensure consistent product quality and commercial viability.

5. Conclusion

Curcumin-loaded nanoparticles represent a significant advancement in nanomedicine by addressing the major limitations associated with conventional curcumin formulations, particularly poor solubility, low bioavailability, rapid metabolism, and chemical instability. Encapsulation within nanocarriers enhances curcumin stability, protects it from degradation, and improves absorption, thereby increasing therapeutic effectiveness. These systems also enable controlled and targeted drug delivery, which can reduce required dosage and minimize side effects. Improved pharmacokinetic behavior has expanded curcumin's potential in treating chronic diseases such as cancer, inflammatory disorders, neurodegenerative conditions, and metabolic diseases. Despite encouraging progress, challenges related to large-scale manufacturing, formulation stability, safety evaluation, and regulatory approval still need careful consideration. Long-term toxicity studies and standardized characterization methods are essential for clinical acceptance. Continued interdisciplinary collaboration among pharmaceutical scientists, nanotechnologists, clinicians, and regulatory bodies will support further advancement. Integration of advanced formulation strategies and innovative delivery technologies may accelerate clinical translation. Additionally, scalable production methods will be crucial for commercialization. With ongoing research and technological innovation, curcumin nanoparticles are expected to gain broader clinical relevance. Overall, they hold strong promise for improving therapeutic outcomes in modern healthcare.

References

1. Lalong, P. R. F., Refdi, C. W., Une, S., Sayuti, M., & Iswadi, D. (2025). Bioavailability of curcumin in various nanoformulations: A critical review. Asian Journal of Applied Research for Community Development and Empowerment, 9(3), 409–416. https://doi.org/10.29165/ajarcde.v9i3.861
2. Kanwal, Q., Ahmed, M., Hamza, M., Ahmad, M., Rehman, A., Yousaf, N., Javaid, A., Anwar, A., Khan, I. H., & Muddassar, M. (2023). Curcumin nanoparticles: Physicochemical fabrication, characterization, antioxidant, enzyme inhibition, molecular docking and simulation studies. RSC Advances, 13, 22268–22280. https://doi.org/10.1039/D3RA01432K
3. Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A review of its effects on human health. Foods, 6(10), 92.
4. Salehi, B., Stojanović-Radić, Z., Matejić, J., et al. (2019). The therapeutic potential of curcumin: A review. Phytotherapy Research, 33(12), 2921–2937.
5. Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013). Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS Journal, 15, 195–218.
6. Prasad, S., Gupta, S. C., Tyagi, A. K., & Aggarwal, B. B. (2014). Curcumin, a component of turmeric: From farm to pharmacy. BioFactors, 40, 2–13.
7. Yallapu, M. M., Jaggi, M., & Chauhan, S. C. (2012). Curcumin nanoformulations: A future nanomedicine for cancer. Drug Discovery Today, 17, 71–80.
8. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4, 807–818.
9. Shaikh, J., Ankola, D. D., Beniwal, V., Singh, D., & Kumar, M. N. (2009). Nanoparticle encapsulation improves oral bioavailability of curcumin. Journal of Agricultural and Food Chemistry, 57, 105–112.
10. Wang, Y., Lu, Z., Wu, H., & Lv, F. (2009). Study on preparation of curcumin nanoparticles. Food Chemistry, 113, 1321–1327.
11. Bisht, S., Feldmann, G., Soni, S., et al. (2007). Polymeric nanoparticle-encapsulated curcumin: A novel strategy for cancer therapy. Journal of Nanobiotechnology, 5, 3.
12. Sahu, A., Bora, U., Kasoju, N., & Goswami, P. (2008). Synthesis of novel biodegradable polymeric nanoparticles for curcumin delivery. Nanomedicine, 4, 76–83.

13. Moballegh Nasery, M., Abadi, B., Poormoghadam, D., et al. (2020). Curcumin delivery mediated by bio-based nanoparticles. Molecules, 25, 689.
14. Sun, M., Su, X., Ding, B., et al. (2012). Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine, 7, 1085–1100.
15. Kunnumakkara, A. B., Bordoloi, D., Padmavathi, G., et al. (2017). Curcumin, the golden nutraceutical. Cancer Letters, 377, 8–19.
16. Amalraj, A., Pius, A., Gopi, S., & Gopi, S. (2017). Biological activities of curcuminoids. Journal of Traditional and Complementary Medicine, 7, 205–233.
17. Tønnesen, H. H., & Karlsen, J. (1985). Studies on curcumin stability. Zeitschrift für Lebensmittel-Untersuchung und Forschung, 180, 132–134.
18. Ghosh, S., Banerjee, S., & Sil, P. C. (2015). The beneficial role of curcumin on inflammation and oxidative stress. Molecular Nutrition & Food Research, 59, 1205–1225.
19. Nelson, K. M., Dahlin, J. L., Bisson, J., et al. (2017). The essential medicinal chemistry of curcumin. Journal of Medicinal Chemistry, 60, 1620–1637.
20. Mohanty, C., & Sahoo, S. K. (2010). Curcumin and its topical formulations. Expert Opinion on Drug Delivery, 7, 1–20.
21. Kakkar, V., Singh, S., Singla, D., et al. (2011). Exploring solid lipid nanoparticles for topical delivery of curcumin. Drug Development and Industrial Pharmacy, 37, 1039–1047.
22. Yadav, V. R., Prasad, S., Sung, B., & Aggarwal, B. B. (2011). Curcumin delivery by nanoparticles. Molecular Nutrition & Food Research, 55, 409–424.
23. El-Sayed, H. S., Ibrahim, H. R., & Mahmoud, R. A. (2024). Advances in nanocarrier systems for overcoming formulation challenges of curcumin. Nanomaterials, 14(8), 672.